Skip to main content
. 2023 Jan 30;15(2):455. doi: 10.3390/pharmaceutics15020455

Figure 4.

Figure 4

UMBO increased the delivery of ICIs to the brain parenchyma. (Panel A): IHC staining of anti-PD-L1 (BXCELL) (Panel B): PK of Nivolumab concentration in the C57BL/6 mice blood and brain. (Panel C): Brain/plasma ratio of nivolumab concentration over time. UMBO enhanced the brain/plasma ratio of nivolumab compared to control mice. ** for p ≤ 0.01. **** for p ≤ 0.0001.